Inmarsat Extends Partnership With CSG To Empower Cloud-Based Monetisation of Its Mobile Broadband Services
4.11.2020 11:00:00 EET | Business Wire | Press release
CSG ® (NASDAQ: CSGS) today announced that it has expanded its relationship with Inmarsat, a leader in global, mobile satellite communications. As part of this multi-year agreement, Inmarsat is moving its billing and revenue management operations to a consolidated, cloud-based managed services model developed by CSG, replacing existing third-party and bespoke legacy solutions.
“For nearly 20 years, CSG has worked with Inmarsat to get the most out of our billing and revenue management operations, enabling the introduction of new products and services while increasing efficiencies across our business,” said David Thornhill, senior vice president, Group IT Inmarsat. “By moving to a cloud-based managed services model, CSG will foster a more agile, cost-effective approach to how we operate our retail and wholesale business while creating a sustainable model for future success."
By utilising the CSG managed services solution, the British operator will benefit from increased process agility, go-to-market flexibility, and access to precision insights across all operations, while streamlining billing operations and lowering operating expenditures that were associated with prior third-party solutions.
The new agreement deploys the latest versions of CSG Singleview, CSG Interconnect, and CSG Intermediate, already in use by Inmarsat, helping them maximise profitability, reduce operational costs, and meet customer demands in real-time. Additional capabilities facilitate proactive identification and resolution of customer issues. In its entirety, the new cloud-based solution provides a future-proof architecture that takes advantage of best practices in billing and revenue management and enhances the customer experience.
“As Inmarsat looks to advance satellite, airborne, and maritime connectivity across Europe and beyond, we look forward to continuing our long-standing partnership, supporting the optimisation of their billing and revenue management operations, while helping them minimise risk and lower operating costs,” said James Kirby, head of CSG's EMEA business. “We are thrilled to expand our relationship with Inmarsat to help grow the business across their entire portfolio.”
CSG is recognised as a leader in the Gartner Magic Quadrant for its Revenue and Customer Management solutions, supporting hundreds of millions of end-users worldwide. The company provides monetisation, settlement and customer care solutions that help clients launch innovative digital services while transitioning off legacy systems at their own pace. CSG’s Wholesale Business Management Solution has won multiple awards for its cloud functionality and innovation and received the Global Stratecast CSP Monetisation Interconnect & Settlement Market Leadership Award from Frost & Sullivan in recent years.
About CSG
For more than 35 years, CSG has simplified the complexity of business, delivering innovative customer engagement solutions that help companies acquire, monetise, engage, and retain customers. Operating across more than 120 countries worldwide, CSG manages billions of critical customer interactions annually, and its award-winning suite of software and services allow companies across dozens of industries to tackle their biggest business challenges and thrive in an ever-changing marketplace.
CSG is the trusted partner for driving digital innovation for hundreds of leading global brands, including AT&T, Charter Communications, Comcast, DISH, Eastlink, Formula One, MTN and Telstra.
To learn more, visit our website at csgi.com and connect with us on LinkedIn and Twitter.
Copyright © 2020 CSG Systems International, Inc. and/or its affiliates (“CSG”). All rights reserved. CSG® is a registered trademark of CSG Systems International, Inc. All third-party trademarks, service marks, and/or product names which are referenced in this document are the property of their respective owners, and all rights therein are reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201104005049/en/
Contact information
Brad Jones
Global / North America / Asia-Pacific Public Relations
CSG
+1 (303) 200-3001
brad.jones@csgi.com
Kristine Østergaard
CSG
Europe / Middle East / Africa Public Relations
+44 (0)79 2047 7204
kristine.ostergaard@csgi.com
Liz Bauer
Investor Relations
CSG
+1 (303) 804-4065
liz.bauer@csgi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom